Sugi Predict

Sugi Predict / Compounds / Sucrosofate

Sucrosofate

Sucrosofate

SCHEMBL19358882

CCNCC.O=S(=O)(O)OC[C@H]1O[C@@](COS(=O)(=O)O)(O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TOP1

The experimentally established mechanism targets of Sucrosofate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ FGF1 P05230 5/20 0.65
▸ FGF2 P09038 5/20 0.65
▸ SERPINC1 P01008 1/20 0.35
▸ HPSE Q9Y251 13/20 0.32
▸ VEGFA P15692 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sucrosofate SCHEMBL16661862 0.93 FGF1 (0.74) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL145070 0.93 FGF1 (0.74) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL18467935 0.93 FGF1 (0.74) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL145069 0.93 FGF1 (0.74) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL16661861 0.93 FGF1 (0.74) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL18742107 0.92 FGF1 (0.72) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL921799 0.92 FGF1 (0.72) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL2063889 0.90 FGF1 (0.65) FGF1FGF2SERPINC1HPSEVEGFA
Sucrosofate SCHEMBL18244210 0.90 FGF1 (0.65) FGF1FGF2SERPINC1HPSEVEGFA
Water SCHEMBL41379 0.83 FGF1 (0.61) FGF1FGF2SERPINC1HPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023051799-A1 VINORELBINE TARTRATE LIPOSOME, AND RAW MATERIAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海济煜医药科技有限公司 2023-04-06 — — WO disclosed
CN-109310782-A Ephrin receptor A2(EphA2) targeted docetaxel generating nanoliposome composition 梅里麦克制药股份有限公司 2019-02-05 — — CN disclosed
EP-3429631-A1 TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS Merrimack Pharmaceuticals, Inc. (US) 2019-01-23 — — EP disclosed
EP-3429629-A1 EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS Merrimack Pharmaceuticals, Inc. (US) 2019-01-23 — — EP disclosed
WO-2017161071-A1 TREATING EPHRIN RECEPTOR A2 (EPHA2) POSITIVE CANCER WITH TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS MERRIMACK PHARMACEUTICALS, INC (US) 2017-09-21 — — WO disclosed
WO-2017161067-A1 EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSITIONS MERRIMACK PHARMACEUTICALS, INC (US) 2017-09-21 — — WO disclosed
Send feedback